Rein Willemze

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4579468/publications.pdf

Version: 2024-02-01

573 papers 39,056 citations

99 h-index 173 g-index

583 all docs

583
docs citations

583 times ranked 18372 citing authors

#	Article	IF	Citations
1	WHO-EORTC classification for cutaneous lymphomas. Blood, 2005, 105, 3768-3785.	0.6	3,529
2	EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood, 1997, 90, 354-71.	0.6	908
3	The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood, 2019, 133, 1703-1714.	0.6	846
4	Autologous or Allogeneic Bone Marrow Transplantation Compared with Intensive Chemotherapy in Acute Myelogenous Leukemia. New England Journal of Medicine, 1995, 332, 217-223.	13.9	804
5	Primary and secondary cutaneous CD30+lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood, 2000, 95, 3653-3661.	0.6	741
6	Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood, 2008, 111, 838-845.	0.6	617
7	Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the †cutaneous variant'1. British Journal of Haematology, 2004, 127, 173-183.	1.2	535
8	Primary Cutaneous CD8-Positive Epidermotropic Cytotoxic T Cell Lymphomas. American Journal of Pathology, 1999, 155, 483-492.	1.9	476
9	Update on erythrodermic cutaneous T-cell lymphoma: Report of the international society for cutaneous lymphomas. Journal of the American Academy of Dermatology, 2002, 46, 95-106.	0.6	448
10	Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 2742-2747.	3.3	400
11	Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood, 1997, 90, 1014-21.	0.6	375
12	European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017. European Journal of Cancer, 2017, 77, 57-74.	1.3	363
13	Melanocortin 1 Receptor (MC1R) Gene Variants are Associated with an Increased Risk for Cutaneous Melanoma Which is Largely Independent of Skin Type and Hair Color. Journal of Investigative Dermatology, 2001, 117, 294-300.	0.3	351
14	Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. Journal of the American Academy of Dermatology, 1993, 28, 973-980.	0.6	339
15	Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. Journal of Clinical Oncology, 2015, 33, 3766-3773.	0.8	328
16	Primary cutaneous CD30-positive large cell lymphoma: Definition of a new type of cutaneous lymphoma with a favorable prognosis.A European multicenter study of 47 patients. Cancer, 1993, 71, 2097-2104.	2.0	326
17	Mycosis Fungoides. Archives of Dermatology, 2000, 136, 504-10.	1.7	313
18	WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. Journal of Cutaneous Pathology, 2005, 32, 647-674.	0.7	313

#	Article	IF	CITATIONS
19	Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres. British Journal of Haematology, 2001, 113, 209-216.	1.2	307
20	The Influence of Painful Sunburns and Lifetime Sun Exposure on the Risk of Actinic Keratoses, Seborrheic Warts, Melanocytic Nevi, Atypical Nevi, and Skin Cancer. Journal of Investigative Dermatology, 2003, 120, 1087-1093.	0.3	281
21	Reclassification of 300 Primary Cutaneous B-Cell Lymphomas According to the New WHO–EORTC Classification for Cutaneous Lymphomas: Comparison With Previous Classifications and Identification of Prognostic Markers. Journal of Clinical Oncology, 2007, 25, 1581-1587.	0.8	278
22	Follicular Mycosis Fungoides, a Distinct Disease Entity With or Without Associated Follicular Mucinosis. Archives of Dermatology, 2002, 138, 191-8.	1.7	277
23	CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma Journal of Clinical Oncology, 1998, 16, 3257-3263.	0.8	272
24	Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood, 2005, 105, 3671-3678.	0.6	266
25	Activation of the <i>c-myc </i> Oncogene in a Precursor-B-Cell Blast Crisis of Follicular Lymphoma, Presenting as Composite Lymphoma. New England Journal of Medicine, 1988, 318, 1373-1378.	13.9	254
26	Prognostic Factors in Primary Cutaneous Large B-Cell Lymphomas: A European Multicenter Study. Journal of Clinical Oncology, 2001, 19, 3602-3610.	0.8	251
27	KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia, 2009, 23, 492-500.	3.3	236
28	Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the Metalloproteinase gelatinase B (MMP-9). Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 10863-10868.	3.3	225
29	Epigenetic Profiling of Cutaneous T-Cell Lymphoma: Promoter Hypermethylation of Multiple Tumor Suppressor Genes Including BCL7a, PTPRG, and p73. Journal of Clinical Oncology, 2005, 23, 3886-3896.	0.8	224
30	Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood, 2003, 102, 2213-2219.	0.6	221
31	An Immunodeficiency Disease with <i>RAG</i> Mutations and Granulomas. New England Journal of Medicine, 2008, 358, 2030-2038.	13.9	219
32	Response to Interferon Alfa-2b in a Patient with Systemic Mastocytosis. New England Journal of Medicine, 1992, 326, 619-623.	13.9	212
33	The clinical and histological spectrum of lymphomatoid papulosis. British Journal of Dermatology, 1982, 107, 131-144.	1.4	210
34	Treatment of T-cell prolymphocytic leukemia with human CD52 antibody Journal of Clinical Oncology, 1997, 15, 2667-2672.	0.8	202
35	The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. British Journal of Haematology, 2001, 112, 950-958.	1.2	200
36	Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 10972-10977.	3.3	196

#	Article	IF	CITATIONS
37	Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. Journal of the American Academy of Dermatology, 2002, 47, 364-370.	0.6	194
38	CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Annals of Oncology, 2004, 15, 1097-1108.	0.6	191
39	Oncogenomic analysis of mycosis fungoides reveals major differences with Sézary syndrome. Blood, 2009, 113, 127-136.	0.6	188
40	Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood, 2012, 119, 1643-1649.	0.6	186
41	Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T-cell or null cell phenotype. Histopathology, 1993, 23, 127-135.	1.6	179
42	Primary cutaneous large cell lymphomas of follicular center cell origin. Journal of the American Academy of Dermatology, 1987, 16, 518-526.	0.6	177
43	Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. British Journal of Dermatology, 2003, 149, 363-369.	1.4	177
44	Novel and Highly Recurrent Chromosomal Alterations in Seleary Syndrome. Cancer Research, 2008, 68, 2689-2698.	0.4	176
45	Indolent CD8-positive Lymphoid Proliferation of the Ear. American Journal of Surgical Pathology, 2007, 31, 1887-1892.	2.1	175
46	Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2013, 24, vi149-vi154.	0.6	175
47	Primary Cutaneous Marginal Zone B-Cell Lymphoma. Archives of Dermatology, 2005, 141, 1139.	1.7	173
48	Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2018, 29, iv30-iv40.	0.6	171
49	Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions. Haematologica, 2007, 92, 486-492.	1.7	164
50	Increased Risk of Cancer Other Than Melanoma in CDKN2A Founder Mutation (p16-Leiden)-Positive Melanoma Families. Clinical Cancer Research, 2008, 14, 7151-7157.	3.2	161
51	Neutrophils are indispensable for hematopoietic stem cell mobilization induced by interleukin-8 in mice. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 6228-6233.	3.3	160
52	Cutaneous immunocytomas: a clinicopathologic study of 26 cases. Histopathology, 1993, 23, 117-125.	1.6	158
53	Granulomatous Mycosis Fungoides and Granulomatous Slack Skin. Archives of Dermatology, 2008, 144, 1609-17.	1.7	158
54	Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood, 2001, 98, 2326-2331.	0.6	155

#	Article	IF	Citations
55	Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance. British Journal of Dermatology, 2003, 149, 1183-1191.	1.4	155
56	Aberrant Expression of the Tyrosine Kinase Receptor EphA4 and the Transcription Factor Twist in Sézary Syndrome Identified by Gene Expression Analysis. Cancer Research, 2004, 64, 5578-5586.	0.4	155
57	Inhibition of human macrophage colony formation by interleukin 4 Journal of Experimental Medicine, 1989, 170, 577-582.	4.2	154
58	Primary extranodal and nodal non-Hodgkin's lymphoma. European Journal of Cancer & Clinical Oncology, 1989, 25, 1203-1210.	0.9	153
59	The prognosis of patients with lymphomatoid papulosis associated with malignant lymphomas. British Journal of Dermatology, 1992, 126, 596-602.	1.4	149
60	Expression of Programmed Death-1 in Primary Cutaneous CD4-Positive Small/Medium-Sized Pleomorphic T-Cell Lymphoma, Cutaneous Pseudo-T-Cell Lymphoma, and Other Types of Cutaneous T-Cell Lymphoma. American Journal of Surgical Pathology, 2012, 36, 109-116.	2.1	148
61	Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia Journal of Experimental Medicine, 1992, 176, 1283-1289.	4.2	147
62	Low-Dose Palliative Radiotherapy for Cutaneous B- and T-Cell Lymphomas. International Journal of Radiation Oncology Biology Physics, 2009, 74, 154-158.	0.4	142
63	Human IP-9: A Keratinocyte-Derived High Affinity CXC-Chemokine Ligand for the IP-10/Mig Receptor (CXCR3)1. Journal of Investigative Dermatology, 1999, 112, 716-722.	0.3	140
64	Treatment of primary cutaneous B-cell lymphomas of follicle center cell origin: a clinical follow-up study of 55 patients treated with radiotherapy or polychemotherapy Journal of Clinical Oncology, 1996, 14, 549-555.	0.8	137
65	Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood, 2007, 109, 1720-1727.	0.6	137
66	bcl-2 protein expression in primary cutaneous large B-cell lymphoma is site-related Journal of Clinical Oncology, 1998, 16, 2080-2085.	0.8	136
67	Transplantation of Peripheral Blood Stem Cells as Compared With Bone Marrow From HLA-Identical Siblings in Adult Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2002, 20, 4655-4664.	0.8	136
68	Effect of Smoking and Sun on the Aging Skin. Journal of Investigative Dermatology, 2003, 120, 548-554.	0.3	135
69	Evolution of acquired severe aplastic anaemia to myelodysplasia and subsequent leukaemia in adults. British Journal of Haematology, 1988, 70, 55-62.	1.2	134
70	Megakaryoblastic Leukaemia (Acute Myelofibrosis): a Report of Three Cases. British Journal of Haematology, 1979, 42, 9-20.	1.2	132
71	Most Primary Cutaneous CD30-Positive Lymphoproliferative Disorders Have a CD4-Positive Cytotoxic T-Cell Phenotype. Journal of Investigative Dermatology, 1997, 109, 636-640.	0.3	131
72	Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia, 2004, 18, 316-325.	3. 3	131

#	Article	IF	CITATIONS
73	The PROCLIPI international registry of earlyâ€stage mycosis fungoides identifies substantial diagnostic delay in most patients. British Journal of Dermatology, 2019, 181, 350-357.	1.4	127
74	Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood, 2000, 95, 3653-61.	0.6	127
75	Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes Journal of Experimental Medicine, 1991, 174, 27-33.	4.2	126
76	Array-Based Comparative Genomic Hybridization Analysis Reveals Recurrent Chromosomal Alterations and Prognostic Parameters in Primary Cutaneous Large B-Cell Lymphoma. Journal of Clinical Oncology, 2006, 24, 296-305.	0.8	125
77	Prognostic significance of CD30 (Ki-1/Ber-H2) expression in primary cutaneous large-cell lymphomas of T-cell origin. A clinicopathologic and immunohistochemical study in 20 patients. American Journal of Pathology, 1989, 135, 1169-78.	1.9	124
78	Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study Journal of Clinical Oncology, 1990, 8, 287-294.	0.8	122
79	Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy. Haematologica, 2009, 94, 1316-1320.	1.7	121
80	Results of Radiotherapy in 153 Primary Cutaneous B-Cell Lymphomas Classified According to the WHO-EORTC Classification. Archives of Dermatology, 2007, 143, 1520.	1.7	120
81	Clinical Staging and Prognostic Factors in Folliculotropic Mycosis Fungoides. JAMA Dermatology, 2016, 152, 992.	2.0	119
82	DFFRY codes for a new human male-specific minor transplantation antigen involved in bone marrow graft rejection. Blood, 2000, 95, 1100-1105.	0.6	117
83	Classification of cutaneous T-cell lymphoma: from Alibert to WHO-EORTC. Journal of Cutaneous Pathology, 2006, 33, 18-26.	0.7	117
84	The CXCR3 Activating Chemokines IP-10, Mig, and IP-9 are Expressed in Allergic but not in Irritant Patch Test Reactions. Journal of Investigative Dermatology, 1999, 113, 574-578.	0.3	116
85	MicroRNA-21 Expression in CD4+ T Cells Is Regulated by STAT3 and Is Pathologically Involved in Sézary Syndrome. Journal of Investigative Dermatology, 2011, 131, 762-768.	0.3	116
86	Characterization of T-Cell Subpopulations in Skin and Peripheral Blood of Patients with Cutaneous T-Cell Lymphomas and Benign Inflammatory Dermatoses. Journal of Investigative Dermatology, 1983, 80, 60-66.	0.3	115
87	Repeat polymorphisms in the interleukin-4 gene (IL4). Nucleic Acids Research, 1991, 19, 3763-3763.	6.5	115
88	Classification of primary cutaneous T-cell lymphomas. Histopathology, 1994, 24, 405-415.	1.6	113
89	Differential Expression of Programmed Death-1 (PD-1) in $S\tilde{A}$ ©zary Syndrome and Mycosis Fungoides. Archives of Dermatology, 2012, 148, 1379.	1.7	113
90	Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma. Annals of Oncology, 2004, 15, 1215-1221.	0.6	111

#	Article	IF	CITATIONS
91	Human Mesenchymal Stem Cells Derived from Bone Marrow Display a Better Chondrogenic Differentiation Compared with Other Sources. Connective Tissue Research, 2007, 48, 132-140.	1.1	110
92	Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria. Haematologica, 2012, 97, 1666-1673.	1.7	110
93	Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial. Bone Marrow Transplantation, 1997, 20, 307-315.	1.3	108
94	The early phase of engraftment after murine blood cell transplantation is mediated by hematopoietic stem cells. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 725-729.	3.3	108
95	Primary gastrointestinal non-Hodgkin's lymphoma in a population-based registry. British Journal of Cancer, 1989, 60, 745-750.	2.9	106
96	Rejection of bone-marrow graft by recipient-derived cytotoxic T lymphocytes against minor histocompatibility antigens. Lancet, The, 1990, 335, 131-134.	6.3	105
97	Treatment of Multifocal Primary Cutaneous B-Cell Lymphoma: A Clinical Follow-Up Study of 29 Patients. Journal of Clinical Oncology, 1999, 17, 2471-2471.	0.8	105
98	CD8+ T Cells in Cutaneous T-Cell Lymphoma: Expression of Cytotoxic Proteins, Fas Ligand, and Killing Inhibitory Receptors and Their Relationship With Clinical Behavior. Journal of Clinical Oncology, 2001, 19, 4322-4329.	0.8	105
99	Molecular Cytogenetic Analysis of Chromosomal Breakpoints in the IGH, MYC, BCL6, and MALT1 Gene Loci in Primary Cutaneous B-cell Lymphomas. Journal of Investigative Dermatology, 2004, 123, 213-219.	0.3	105
100	Photodynamic Therapy does not Prevent Cutaneous Squamous-Cell Carcinoma in Organ-Transplant Recipients: Results of a Randomized-Controlled Trial. Journal of Investigative Dermatology, 2006, 126, 569-574.	0.3	105
101	Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL. British Journal of Dermatology, 2000, 143, 313-319.	1.4	103
102	Subsequent Squamous- and Basal-Cell Carcinomas in Kidney-Transplant Recipients After the First Skin Cancer: Cumulative Incidence and Risk Factors. Transplantation, 2010, 89, 1231-1238.	0.5	102
103	Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Lancet, The, 2000, 355, 1393-1398.	6.3	99
104	Replacement of animal-derived collagen matrix by human fibroblast-derived dermal matrix for human skin equivalent products. Biomaterials, 2009, 30, 71-78.	5.7	99
105	Modification of rhodamine staining allows identification of hematopoietic stem cells with preferential short-term or long-term bone marrow-repopulating ability Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 8901-8905.	3.3	98
106	Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Annals of Oncology, 2017, 28, 2517-2525.	0.6	98
107	Histopathologic studies in Sézary syndrome and erythrodermic mycosis fungoides: A comparison with benign forms of erythroderma. Journal of the American Academy of Dermatology, 1986, 15, 1217-1226.	0.6	96
108	The addition of rituximab to anthracyclineâ€based chemotherapy significantly improves outcome in â€~Western' patients with intravascular large Bâ€cell lymphoma. British Journal of Haematology, 2008, 143, 253-257.	1.2	96

#	Article	IF	Citations
109	The majority of cutaneous marginal zone B-cell lymphomas expresses class-switched immunoglobulins and develops in a T-helper type 2 inflammatory environment. Blood, 2008, 112, 3355-3361.	0.6	92
110	Applicability and Prognostic Value of the New TNM Classification System in 135 Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma. Archives of Dermatology, 2009, 145, 1399-404.	1.7	92
111	miRNA expression profiling of mycosis fungoides. Molecular Oncology, 2011, 5, 273-280.	2.1	91
112	Cutaneous pseudo-T-cell lymphomas. A clinicopathologic study of 20 patients. Cancer, 1992, 69, 717-724.	2.0	89
113	Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation. Annals of Oncology, 2013, 24, 2430-2434.	0.6	89
114	Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells. Human Immunology, 1997, 53, 216-223.	1.2	88
115	Gemtuzumab ozogamicin (Mylotarg®) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups. Leukemia. 2005. 19. 1768-1773.	3.3	88
116	Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development. International Journal of Cancer, 2003, 106, 472-479.	2.3	86
117	lgM Expression on Paraffin Sections Distinguishes Primary Cutaneous Large B-cell Lymphoma, Leg Type From Primary Cutaneous Follicle Center Lymphoma. American Journal of Surgical Pathology, 2010, 34, 1043-1048.	2.1	86
118	Aggressive epidermotropic cutaneous <scp>CD</scp> 8 ⁺ lymphoma: a cutaneous lymphoma with distinct clinical and pathological features. Report of an <scp>EORTC</scp> Cutaneous Lymphoma Task Force Workshop. Histopathology, 2015, 67, 425-441.	1.6	86
119	Differentiation between lymphadenosis benigna cutis and primary cutaneous follicular center cell lymphomas a comparative clinicopathologic study of 57 patients. Cancer, 1990, 65, 2301-2306.	2.0	85
120	T cells recognizing leukemic CD34+ progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 10152-10157.	3.3	85
121	Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). British Journal of Haematology, 2001, 115, 895-902.	1.2	84
122	Fine-Mapping Chromosomal Loss at 9p21: Correlation with Prognosis in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. Journal of Investigative Dermatology, 2009, 129, 1149-1155.	0.3	84
123	Mycosis fungoides—like lesions associated with phenytoin and carbamazepine therapy. Journal of the American Academy of Dermatology, 1991, 24, 216-220.	0.6	83
124	Expression of Cytotoxic Proteins by Neoplastic T Cells in Mycosis Fungoides Increases with Progression from Plaque Stage to Tumor Stage Disease. American Journal of Pathology, 1999, 154, 1203-1210.	1.9	82
125	Diagnostic Criteria in Sézary's Syndrome: A Multiparameter Study of Peripheral Blood Lymphocytes in 32 Patients with Erythroderma. Journal of Investigative Dermatology, 1983, 81, 392-397.	0.3	81
126	The influence of HLAâ€matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. British Journal of Haematology, 1998, 102, 1344-1353.	1.2	80

#	Article	IF	CITATIONS
127	Dual HLA class I and class II restricted recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 6806-6811.	3.3	79
128	Interleukin 6 is a permissive factor for monocytic colony formation by human hematopoietic progenitor cells Journal of Experimental Medicine, 1992, 175, 1151-1154.	4.2	78
129	Evaluation of Immunophenotypic and Molecular Biomarkers for Sézary Syndrome Using Standard Operating Procedures: A Multicenter Study of 59 Patients. Journal of Investigative Dermatology, 2016, 136, 1364-1372.	0.3	78
130	Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha. The European Organization for Research and Treatment of Cancer Leukemia Cooperative Group Journal of Clinical Oncology, 1989, 7, 1533-1538.	0.8	77
131	Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes Journal of Clinical Investigation, 1995, 96, 877-883.	3.9	77
132	Efficacy of a hypofractionated schedule in electron beam radiotherapy for epithelial skin cancer: Analysis of 434 cases. Radiotherapy and Oncology, 2010, 95, 245-249.	0.3	75
133	A Meta-Analysis of Gene Expression Data Identifies a Molecular Signature Characteristic for Tumor-Stage Mycosis Fungoides. Journal of Investigative Dermatology, 2012, 132, 2050-2059.	0.3	75
134	EORTC Classification for Primary Cutaneous Lymphomas: The Best Guide to Good Clinical Management. American Journal of Dermatopathology, 1999, 21, 265-273.	0.3	75
135	Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood, 1999, 94, 1201-8.	0.6	75
136	Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. American Journal of Clinical Pathology, 2005, 123, 662-75.	0.4	75
137	Cucurbitacin I Inhibits Stat3 and Induces Apoptosis in Sézary Cells. Journal of Investigative Dermatology, 2008, 128, 1691-1695.	0.3	74
138	The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia. British Journal of Cancer, 1991, 64, 144-148.	2.9	73
139	Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial. Haematologica, 2010, 95, 1754-1761.	1.7	73
140	Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40. Leukemia, 2011, 25, 1697-1703.	3.3	73
141	High Dose Cytosine Arabinoside in the Management of Refractory Acute Leukaemia. Scandinavian Journal of Haematology, 1982, 29, 141-146.	0.0	71
142	Diffuse large cell lymphomas of follicular center cell origin presenting in the skin. A clinicopathologic and immunologic study of 16 patients. American Journal of Pathology, 1987, 126, 325-33.	1.9	71
143	Demonstration of Clonal Immunoglobulin Gene Rearrangements in Cutaneous B-Cell Lymphomas and Pseudo–B-Cell Lymphomas: Differential Diagnostic and Pathogenetic Aspects. Journal of Investigative Dermatology, 1992, 99, 749-754.	0.3	69
144	Biology of IL-8-Induced Stem Cell Mobilization. Annals of the New York Academy of Sciences, 1999, 872, 71-82.	1.8	69

#	Article	ΙF	Citations
145	Aberrant DNA Methylation in Cutaneous Malignancies. Seminars in Oncology, 2005, 32, 479-487.	0.8	69
146	High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma. Blood, 2018, 131, 2086-2089.	0.6	69
147	Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous Bâ€cell lymphoma. British Journal of Haematology, 2008, 142, 52-56.	1.2	68
148	Identification of phosphatidylinositol 4-kinase type II \hat{l}^2 as HLA class II-restricted target in graft versus leukemia reactivity. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3837-3842.	3.3	68
149	Cytotoxic T-lymphocyte (CTL) responses against acute or chronic myeloid leukemia. Immunological Reviews, 1997, 157, 223-230.	2.8	67
150	Epidermal Interferon- \hat{I}^3 Inducible Protein-10 (IP-10) and Monokine Induced by \hat{I}^3 -Interferon (Mig) but not IL-8 mRNA Expression is Associated with Epidermotropism in Cutaneous T Cell Lymphomas. Journal of Investigative Dermatology, 1998, 111, 222-226.	0.3	67
151	VH Gene Analysis of Primary Cutaneous B-Cell Lymphomas: Evidence for Ongoing Somatic Hypermutation and Isotype Switching. Blood, 1998, 92, 3857-3864.	0.6	67
152	Chromosomal Aberration Patterns Differ in Subtypes of Primary Cutaneous B Cell Lymphomas. Journal of Investigative Dermatology, 2004, 122, 1495-1502.	0.3	67
153	Histopathological and immunophenotypical criteria for the diagnosis of Sézary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 9. British Journal of Dermatology, 2015, 173, 93-105.	1.4	67
154	Leiden reconstructed human epidermal model as a tool for the evaluation of the skin corrosion and irritation potential according to the ECVAM guidelines. Toxicology in Vitro, 2008, 22, 1311-1320.	1.1	66
155	Combined CD8+ and CD4+ adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection. Haematologica, 2010, 95, 1943-1951.	1.7	66
156	Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years. Leukemia, 1997, 11, 416-419.	3.3	65
157	The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial. Leukemia, 2003, 17, 60-67.	3.3	65
158	Non–Mycosis Fungoides Cutaneous T-Cell Lymphomas. American Journal of Clinical Pathology, 2013, 139, 491-514.	0.4	64
159	Immunohistochemical Studies of Lymphadenosis Benigna Cutis Occurring in a Tattoo. American Journal of Dermatopathology, 1988, 10, 518-523.	0.3	63
160	The generation of dendritic-like cells with increased allostimulatory function from acute myeloid leukemia cells of various FAB subclasses. Human Immunology, 2000, 61, 565-574.	1.2	63
161	Incidence of cancer in kidney-transplant recipients: A long-term cohort study in a single center. Cancer Epidemiology, 2011, 35, 105-111.	0.8	63
162	Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group Journal of Clinical Oncology, 1997, 15, 476-482.	0.8	62

#	Article	IF	CITATIONS
163	Cutaneous Anaplastic Large Cell Lymphoma and Peripheral T-Cell Lymphoma NOS Show Distinct Chromosomal Alterations and Differential Expression of Chemokine Receptors and Apoptosis Regulators. Journal of Investigative Dermatology, 2010, 130, 563-575.	0.3	62
164	HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia. Leukemia, 2008, 22, 1387-1394.	3.3	60
165	Generation and administration of HA-1-specific T-cell lines for the treatment of patients with relapsed leukemia after allogeneic stem cell transplantation: a pilot study. Haematologica, 2012, 97, 1205-1208.	1.7	60
166	Mycosis Fungoides. American Journal of Clinical Pathology, 2013, 139, 466-490.	0.4	60
167	Immunological, cytochemical and ultrastructural studies in lymphomatoid papulosis. British Journal of Dermatology, 1983, 108, 381-394.	1.4	59
168	Angiotropic (intravascular) large cell lymphoma of the skin previously classified as malignant angioendotheliomatosis. British Journal of Dermatology, 1987, 116, 393-399.	1.4	59
169	Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders. British Journal of Dermatology, 2009, 161, 121-127.	1.4	59
170	Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio. Leukemia, 2017, 31, 26-33.	3.3	59
171	Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells. Leukemia, 2004, 18, 798-808.	3.3	58
172	Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplantation, 2006, 37, 693-698.	1.3	58
173	Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood, 2022, 140, 419-437.	0.6	58
174	Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors. Leukemia, 2002, 16, 1615-1621.	3.3	57
175	Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath â€in the bag' as T-cell depletion: the Leiden experience. Bone Marrow Transplantation, 2006, 37, 1129-1134.	1.3	57
176	A genomic and expression study of APâ€1 in primary cutaneous Tâ€cell lymphoma: evidence for dysregulated expression of JUNB and JUND in MF and SS. Journal of Cutaneous Pathology, 2008, 35, 899-910.	0.7	57
177	Langerhans cell histiocytosis first presenting in the skin in adults: frequent association with a second haematological malignancy. British Journal of Dermatology, 2012, 167, 1287-1294.	1.4	57
178	Effect of subcutaneously administered human recombinant erythropoietin on erythropoiesis in patients with myelodysplasia. British Journal of Haematology, 1991, 78, 488-493.	1.2	56
179	Chemokine IP-10 expression in cultured human keratinocytes. Archives of Dermatological Research, 1998, 290, 335-341.	1.1	56
180	Lymphomatoid papulosis in children: a study of 10 children registered by the Dutch Cutaneous Lymphoma Working Group. British Journal of Dermatology, 2001, 144, 351-354.	1.4	56

#	Article	IF	CITATIONS
181	Lymphocytic infiltration of the skin (Jessner): a T-cell lymphoproliferative disease. British Journal of Dermatology, 1984, 110, 523-529.	1.4	56
182	Serpina1 is a potent inhibitor of IL-8-induced hematopoietic stem cell mobilization. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 1469-1474.	3.3	56
183	Genomic analysis reveals recurrent deletion of JAKâ€STAT signaling inhibitors <i>HNRNPK</i> and <i>SOCS1</i> in mycosis fungoides. Genes Chromosomes and Cancer, 2018, 57, 653-664.	1.5	56
184	Immunophenotyping and gene rearrangement analysis provide additional criteria to differentiate between cutaneous T-cell lymphomas and pseudo-T-cell lymphomas. American Journal of Pathology, 1997, 150, 1941-9.	1.9	56
185	Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia. Leukemia, 1999, 13, 843-849.	3.3	55
186	Primary cutaneous B-cell lymphoma: classification and treatment. Current Opinion in Oncology, 2006, 18, 425-431.	1.1	55
187	Cutaneous B-Cell Lymphoproliferative Disorders. American Journal of Clinical Pathology, 2013, 139, 515-535.	0.4	55
188	Clinical and histologic differentiation between lymphomatoid papulosis and pityriasis lichenoides. Journal of the American Academy of Dermatology, 1985, 13, 418-428.	0.6	54
189	Nuclear Factor-κB Pathway–Activating Gene Aberrancies in Primary Cutaneous Large B-Cell Lymphoma, Leg Type. Journal of Investigative Dermatology, 2014, 134, 290-292.	0.3	54
190	Mimics of Cutaneous Lymphoma. American Journal of Clinical Pathology, 2013, 139, 536-551.	0.4	53
191	HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT. Blood, 1999, 93, 3863-5.	0.6	53
192	Quantitative skin cultures of Pityrosporum yeasts in patients seropositive for the human immunodeficiency virus with and without seborrheic dermatitis. Journal of the American Academy of Dermatology, 1992, 27, 37-39.	0.6	52
193	Primary cutaneous follicle center lymphoma and primary cutaneous large B-cell lymphoma, leg type, are both targeted by aberrant somatic hypermutation but demonstrate differential expression of AID. Blood, 2006, 107, 4926-4929.	0.6	51
194	Studies on clonality by PCR analysis of the PGK-1 gene. Nucleic Acids Research, 1991, 19, 2794-2794.	6.5	50
195	Monitoring of engraftment and progression of acute lymphoblastic leukemia in individual NOD/SCID mice. Experimental Hematology, 2001, 29, 322-329.	0.2	49
196	The applicability and prognostic value of the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: results on a large cohort of primary cutaneous B-cell lymphomas and comparison with the system used by the Dutch Cutaneous Lymphoma Group. British Journal of Dermatology, 2007, 157, 1205-1211.	1.4	49
197	A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. Annals of Hematology, 1992, 64, 173-180.	0.8	48
198	Problems and possible solutions in finding an unrelated bone marrow donor. Results of consecutive searches for 240 Dutch patients. Bone Marrow Transplantation, 1997, 20, 1011-1017.	1.3	48

#	Article	IF	CITATIONS
199	Cutaneous T-Cell Lymphoma: Epidemiology, Etiology, and Classification. Leukemia and Lymphoma, 2003, 44, S49-S54.	0.6	48
200	Normalized ultraviolet (UV) induction of Langerhans cell depletion and neutrophil infiltrates after artificial UVB hardening of patients with polymorphic light eruption British Journal of Dermatology, 2005, 152, 1268-1274.	1.4	48
201	Expression of B-cell transcription factors in primary cutaneous B-cell lymphoma. Modern Pathology, 2006, 19, 1270-1276.	2.9	48
202	Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation. Haematologica, 2007, 92, 72-80.	1.7	48
203	Skin diseases among schoolchildren in Ghana, Gabon, and Rwanda. International Journal of Dermatology, 2013, 52, 589-600.	0.5	48
204	A novel splice variant of the Fas gene in patients with cutaneous T-cell lymphoma. Cancer Research, 2002, 62, 5389-92.	0.4	48
205	Primary cutaneous anaplastic large cell lymphoma shows a distinct mi <scp>RNA</scp> expression profile and reveals differences from tumorâ€stage mycosis fungoides. Experimental Dermatology, 2012, 21, 632-634.	1.4	47
206	Stage Is a Better Prognostic Indicator than Morphologic Subtype in Primary Noncutaneous T-Cell Lymphoma. American Journal of Clinical Pathology, 1990, 93, 49-57.	0.4	46
207	Diagnostic Value of T-Cell Receptor Beta Gene Rearrangement Analysis on Peripheral Blood Lymphocytes of Patients with Erythroderma. Journal of Investigative Dermatology, 1991, 97, 782-786.	0.3	46
208	Effects of thrombopoietin on the proliferation and differentiation of primitive and mature haemopoietic progenitor cells in cord blood. British Journal of Haematology, 1998, 101, 425-435.	1.2	46
209	Mantle cell lymphoma proliferates upon IL-10 in the CD40 system. Leukemia, 2000, 14, 1483-1489.	3.3	46
210	Expression and induction of costimulatory and adhesion molecules on acute myeloid leukemic cells Implications for adoptive immunotherapy. Experimental Hematology, 2000, 28, 161-168.	0.2	46
211	Minor histocompatibility antigens as targets of graft-versus-leukemia reactions. Current Opinion in Hematology, 2002, 9, 497-502.	1.2	46
212	Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia. Bone Marrow Transplantation, 2002, 30, 243-251.	1.3	46
213	An <i>in vitro</i> threeâ€dimensional model of primary human cutaneous squamous cell carcinoma. Experimental Dermatology, 2009, 18, 849-856.	1.4	46
214	Epigenomic Analysis of Sézary Syndrome Defines Patterns of Aberrant DNA Methylation and Identifies DiagnosticÂMarkers. Journal of Investigative Dermatology, 2016, 136, 1876-1884.	0.3	46
215	Sustained engraftment of mice transplanted with IL-1-primed blood-derived stem cells. Journal of Immunology, 1992, 148, 417-21.	0.4	46
216	Lymphomatoid papulosis and Hodgkin's disease: Are they related?. Archives of Dermatological Research, 1983, 275, 159-167.	1.1	45

#	Article	IF	Citations
217	Respiratory failure elicited by streptococcal septicaemia in patients treated with cytosine arabinoside, and its prevention by penicillin. Infection, 1990, 18, 131-137.	2.3	45
218	Cutaneous pseudolymphomas: classification and differential diagnosis. Seminars in Dermatology, 1994, 13, 187-96.	0.6	45
219	UTY gene codes for an HLA-B60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: characterization of the critical polymorphic amino acid residues for T-cell recognition. Blood, 2000, 96, 3126-32.	0.6	45
220	A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia: A leukemia-lymphoma group trial of the EORTC. Cancer, 1986, 58, 617-623.	2.0	44
221	Immunohistochemical studies in lymphocytic infiltration of the skin (Jessner) and discoid lupus erythematosus. Journal of the American Academy of Dermatology, 1984, 11, 832-840.	0.6	43
222	Pulmonary complications of cytosine-arabinoside therapy: radiographic findings. American Journal of Roentgenology, 1987, 149, 23-27.	1.0	43
223	The biological activities of interleukin-1. Blut, 1989, 59, 147-156.	1.2	43
224	Characterization of the dermal infiltrates in Jessner's lymphocytic infiltrate of the skin, polymorphous light eruption and cutaneous lupus erythematosus: differential diagnostic and pathogenetic aspects. Journal of Cutaneous Pathology, 1990, 17, 2-8.	0.7	43
225	Recommendations for treatment in folliculotropic mycosis fungoides: report of the Dutch Cutaneous Lymphoma Group. British Journal of Dermatology, 2017, 177, 223-228.	1.4	43
226	Cytokine production by the bladder carcinoma cell line 5637: rapid analysis of mRNA expression levels using a cDNA-PCR procedure. Lymphokine and Cytokine Research, 1991, 10, 231-5.	0.7	43
227	Interleukin 1 and poly(rl).poly(rC) induce production of granulocyte CSF, macrophage CSF, and granulocyte-macrophage CSF by human endothelial cells. Experimental Hematology, 1989, 17, 229-34.	0.2	43
228	CD30 expression in normal and neoplastic lymphoid tissue: biological aspects and clinical implications. Leukemia, 1995, 9, 1620-7.	3.3	43
229	A histologic study of lymph nodes from patients with the sézary syndrome. Cancer, 1986, 57, 2375-2380.	2.0	42
230	Lymphomatoid papulosis with a natural killer-cell phenotype British Journal of Dermatology, 2001, 145, 318-322.	1.4	42
231	Deep-Sequencing Analysis Reveals that the miR-199a2/214 Cluster within DNM3os Represents the Vast Majority of Aberrantly Expressed MicroRNAs in Sézary Syndrome. Journal of Investigative Dermatology, 2012, 132, 1520-1522.	0.3	42
232	Methotrexate-associated B-cell Lymphoproliferative Disorders Presenting in the Skin. American Journal of Surgical Pathology, 2014, 38, 999-1006.	2.1	42
233	High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. American Journal of Surgical Pathology, 2018, 42, 1488-1494.	2.1	42
234	Analysis of Major Histocompatibility Antigens and the Mononuclear Cell Infiltrate in Halo Nevi. Journal of Investigative Dermatology, 1985, 85, 25-29.	0.3	41

#	Article	IF	Citations
235	Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL. Bone Marrow Transplantation, 2014, 49, 287-291.	1.3	41
236	TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NK-cell lymphomas) and leukemia cutis. American Journal of Clinical Pathology, 2004, 122, 307-13.	0.4	41
237	Alopecia Mucinosa Progressing into Mycosis Fungoides. American Journal of Dermatopathology, 1988, 10, 478-486.	0.3	40
238	The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study) Tj ETQq0	0 ³ 0 ³ rgBT	/Overlock 10
239	The Role of Interleukin-1 in Hematopoiesis. Acta Haematologica, 1991, 86, 148-154.	0.7	39
240	SUCCESSFUL OUTCOME WITH A ???QUINTUPLE APPROACH??? OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER. Transplantation, 2001, 71, 47-52.	0.5	39
241	More epidermal p53 patches adjacent to skin carcinomas in renal transplant recipients than in immunocompetent patients: the role of azathioprine. Experimental Dermatology, 2008, 17, 349-355.	1.4	39
242	Treatment of earlyâ€stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study*. British Journal of Dermatology, 2021, 184, 722-730.	1.4	39
243	Diffuse cutaneous mastocytosis with multiple cutaneous mastocytomas British Journal of Dermatology, 1980, 102, 601-607.	1.4	38
244	The cell population of cutaneous B-cell lymphomas. British Journal of Dermatology, 1983, 108, 395-409.	1.4	38
245	Peripheral T-cell lymphomas: a clinicopathological and immunological study of 10 cases. Histopathology, 1986, 10, 235-249.	1.6	38
246	Interleukin-4. Blut, 1990, 60, 269-274.	1.2	38
247	Minor histocompatibility antigen-specific cytotoxic T cell lines, capable of lysing human hematopoietic progenitor cells, can be generated in vitro by stimulation with HLA-identical bone marrow cells Journal of Experimental Medicine, 1991, 173, 101-109.	4.2	38
248	Assessment of telomere length in hematopoietic interphase cells using in situ hybridization and digital fluorescence microscopy. Cytometry, 1998, 32, 163-169.	1.8	38
249	Frequency of central nervous system involvement in primary cutaneous B-cell lymphoma. Cancer, 2000, 89, 913-919.	2.0	38
250	Differential Expression of Thymus and Activation Regulated Chemokine and Its Receptor CCR4 in Nodal and Cutaneous Anaplastic Large-Cell Lymphomas and Hodgkin's Disease. Modern Pathology, 2002, 15, 838-844.	2.9	38
251	Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group, Leukemia, 2005, 19, 1929-1933.	3.3	38
252	Differential expression of the HECA-452 antigen (cutaneous lymphocyte associated antigen, CLA) in cutaneous and non-cutaneous T-cell lymphomas. Histopathology, 2007, 21, 59-64.	1.6	38

#	Article	IF	Citations
253	Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application. Haematologica, 2008, 93, 1535-1543.	1.7	38
254	High-dose cytosine arabinoside: pharmacological and clinical aspects. Blut, 1988, 56, 1-11.	1.2	37
255	Pentostatin in T-cell malignancies – a phase II trial of the EORTC. Annals of Oncology, 1999, 10, 1493-1498.	0.6	37
256	Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2010, 21, v177-v180.	0.6	37
257	Autocrine IL-21 Stimulation Is Involved in the Maintenance of Constitutive STAT3 Activation in Sézary Syndrome. Journal of Investigative Dermatology, 2012, 132, 440-447.	0.3	37
258	Multiple minor histocompatibility antigen-specific cytotoxic T lymphocyte clones can be generated during graft rejection after HLA-identical bone marrow transplantation. Bone Marrow Transplantation, 1995, 16, 125-32.	1.3	37
259	Expression of co-stimulatory and adhesion molecules and chemokine or apoptosis receptors on acute myeloid leukaemia: high CD40 and CD11a expression correlates with poor prognosis. British Journal of Haematology, 2001, 115 , $298-308$.	1.2	36
260	DFFRY codes for a new human male-specific minor transplantation antigen involved in bone marrow graft rejection. Blood, 2000, 95, 1100-5.	0.6	36
261	Leucostasis, an underestimated cause of death in leukaemia. Blut, 1988, 56, 39-44.	1.2	35
262	Generation of leukemia-reactive cytotoxic T lymphocytes from HLA-identical donors of patients with chronic myeloid leukemia using modifications of a limiting dilution assay. Bone Marrow Transplantation, 1998, 21, 553-560.	1.3	35
263	Site-Specific Expression of Polycomb-Group Genes Encoding the HPC-HPH/PRC1 Complex in Clinically Defined Primary Nodal and Cutaneous Large B-Cell Lymphomas. American Journal of Pathology, 2004, 164, 533-542.	1.9	35
264	Reticulum cell sarcomas (large cell lymphomas) presenting in the skin. High frequency of true histiocytic lymphoma. Cancer, 1982, 50, 1367-1379.	2.0	34
265	In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2′-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene. Annals of Hematology, 1995, 71, 41-47.	0.8	34
266	EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate. Blood, 2003, 102, 4243-4243.	0.6	34
267	Histiocytic sarcoma (true histiocytic lymphoma): a clinicopathological study of 20 cases. Histopathology, 1984, 8, 105-123.	1.6	33
268	Are most primary cutaneous B-cell lymphomas 'marginal cell lymphomas'?. British Journal of Dermatology, 1995, 133, 950-952.	1.4	33
269	Differential involvement of caspases in apoptosis of myeloid leukemic cells induced by chemotherapy versus growth factor withdrawal. FEBS Letters, 1997, 409, 207-210.	1.3	33
270	The number of nucleated cells reflects the hematopoietic content of umbilical cord blood for transplantation. Bone Marrow Transplantation, 1999, 24, 965-970.	1.3	33

#	Article	IF	CITATIONS
271	Primary cutaneous CD30-positive lymphoproliferative disorders. Hematology/Oncology Clinics of North America, 2003, 17, 1319-1332.	0.9	33
272	Increased Risk of Squamous-Cell Carcinoma in Simultaneous Pancreas Kidney Transplant Recipients Compared with Kidney Transplant Recipients. Journal of Investigative Dermatology, 2009, 129, 2886-2894.	0.3	33
273	Human growth factor (huGRO), interleukin-8 (IL-8) and interferon-Î ³ -inducible protein (Î ³ -IP-10) gene expression in cultured normal human keratinocytes. Archives of Dermatological Research, 1994, 286, 471-475.	1.1	32
274	Intermediate and highâ€dose ARA and mâ€AMSA (or daunorubicin) as remission and consolidation treatment for patients with relapsed acute leukaemia and lymphoblastic nonâ€Hodgkin lymphoma. Scandinavian Journal of Haematology, 1985, 34, 83-87.	0.0	32
275	Proliferation of B cell malignancies in all stages of differentiation upon stimulation in the 'CD40 system'. Leukemia, 1996, 10, 488-93.	3.3	32
276	Primary Plasma Cell Leukaemia. Acta Haematologica, 1983, 70, 122-129.	0.7	31
277	The many faces of lymphocytoma cutis. Journal of the European Academy of Dermatology and Venereology, 2003, 17, 3-6.	1.3	31
278	Frequency and prognosis of associated malignancies in 504 patients with lymphomatoid papulosis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 260-266.	1.3	31
279	T cells selectively infiltrate bone marrow areas with residual haemopoiesis of patients with acquired aplastic anaemia. British Journal of Haematology, 1997, 99, 517-519.	1.2	30
280	High susceptibility of human leukemic cells to Fas-induced apoptosis is restricted to G1 phase of the cell cycle and can be increased by interferon treatment. Leukemia, 2003, 17, 576-584.	3.3	30
281	⟨i>Ex Vivo Expansion and Engraftment Potential of Cord Bloodâ€Derived CD34 ⁺ Cells in NOD/SCID Mice. Annals of the New York Academy of Sciences, 2001, 938, 9-17.	1.8	30
282	Cutaneous Gamma/Delta T-cell Lymphoma During Treatment with Etanercept for Rheumatoid Arthritis. Acta Dermato-Venereologica, 2009, 89, 653-654.	0.6	30
283	Recommendations for treatment of lymphomatoid papulosis with methotrexate: a report from the Dutch Cutaneous Lymphoma Group. British Journal of Dermatology, 2015, 173, 1319-1322.	1.4	30
284	Cutaneous lymphomas with a panniculitic presentation. Seminars in Diagnostic Pathology, 2017, 34, 36-43.	1.0	30
285	EORTC Classification for primary cutaneous lymphomas: A comparison with the R.E.A.L. Classification and the proposed WHO Classification. Annals of Oncology, 2000, 11, S11-S15.	0.6	29
286	Comparison of allogeneic T cell-depleted peripheral blood stem cell and bone marrow transplantation: effect of stem cell source on short- and long-term outcome. Bone Marrow Transplantation, 2001, 27, 1053-1058.	1.3	29
287	Functional characterization of cancerâ€associated fibroblasts of human cutaneous squamous cell carcinoma. Experimental Dermatology, 2011, 20, 737-742.	1.4	29
288	Production of tumor necrosis factor-alpha by normal and malignant B lymphocytes in response to interferon-alpha, interferon-gamma and interleukin-4. Leukemia, 1992, 6, 116-9.	3.3	29

#	Article	IF	CITATIONS
289	Prevention of viridans-group streptococcal septicemia in oncohematologic patients: A controlled comparative study on the effect of penicillin G and cotrimoxazole. Annals of Hematology, 1992, 64, 260-265.	0.8	28
290	Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy. Leukemia, 2004, 18, 1278-1287.	3.3	28
291	From sporadic atypical nevi to familial melanoma: Risk analysis for melanoma in sporadic atypical nevus patients. Journal of the American Academy of Dermatology, 2007, 56, 748-752.	0.6	28
292	Prevalence and causative fungal species of tinea capitis among schoolchildren in Gabon. Mycoses, 2011, 54, e354-9.	1.8	28
293	Cytomegalovirus antigenemia assay or PCR can be used to monitor ganciclovir treatment in bone marrow transplant recipients. Bone Marrow Transplantation, 1992, 9, 247-53.	1.3	28
294	Improved survival of lethally irradiated recipient mice transplanted with circulating progenitor cells mobilized by IL-8 after pretreatment with stem cell factor. Experimental Hematology, 1996, 24, 1387-93.	0.2	28
295	Mycosis fungoides simulating acanthosis nigricans. American Journal of Dermatopathology, 1985, 7, 367-372.	0.3	27
296	Neutropenic enterocolitis following treatment with cytosine arabinoside-containing regimens for hematological malignancies: A potentiating role for amsacrine. Annals of Hematology, 1991, 62, 129-134.	0.8	27
297	Increased risk of second cancers in managing Hodgkin's disease: the 20-year Leiden experience. Annals of Hematology, 1992, 65, 213-218.	0.8	27
298	The occurrence of residual or recurrent squamous cell carcinomas in organ transplant recipients after curettage and electrodesiccation. British Journal of Dermatology, 2006, 154, 493-497.	1.4	27
299	Identification of selectively expressed genes and antigens in CTCL. Experimental Dermatology, 2008, 17, 324-334.	1.4	27
300	Trends of skin diseases in organ-transplant recipients transplanted between 1966 and 2006: a cohort study with follow-up between 1994 and 2006. British Journal of Dermatology, 2010, 162, 390-396.	1.4	27
301	TOX expression in cutaneous T-cell lymphomas: an adjunctive diagnostic marker that is not tumour specific and not restricted to the CD4 ⁺ ACD8 ^{â^'} phenotype. British Journal of Dermatology, 2016, 175, 382-386.	1.4	27
302	Side effects of intermediate- and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute leukaemia and non-Hodgkin's lymphoma. Netherlands Journal of Medicine, 1987, 30, 64-74.	0.6	27
303	HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML). Leukemia, 2000, 14, 859-862.	3.3	26
304	Minor histocompatibility antigen-specific T cells with multiple distinct specificities can be isolated by direct cloning of IFN \hat{I}^3 -secreting T cells from patients with relapsed leukemia responding to donor lymphocyte infusion. Leukemia, 2005, 19, 83-90.	3.3	26
305	Human allo-reactive CD4+ T cells as strong mediators of anti-tumor immunity in NOD/scid mice engrafted with human acute lymphoblastic leukemia. Leukemia, 2012, 26, 312-322.	3.3	26
306	Effects of serially passaged fibroblasts on dermal and epidermal morphogenesis in human skin equivalents. Biogerontology, 2013, 14, 131-140.	2.0	26

#	Article	IF	CITATIONS
307	In vivo use of Campath-1G to prevent graft-versus-host disease and graft rejection after bone marrow transplantation. Bone Marrow Transplantation, 1992, 9, 255-61.	1.3	26
308	Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group. Archives of Dermatology, 1996, 132, 1304-8.	1.7	26
309	Pentoxifylline and skin inflammation. Clinical and Experimental Dermatology, 1998, 23, 168-172.	0.6	25
310	Similar myeloid recovery despite superior overall engraftment in NOD/SCID mice after transplantation of human CD34+ cells from umbilical cord blood as compared to adult sources. Bone Marrow Transplantation, 2001, 28, 163-171.	1.3	25
311	Efficacy and toxicity of gemtuzumab ozogamicin in patients with acute myeloid leukemia. European Journal of Haematology, 2006, 76, 409-413.	1.1	25
312	Clinical, Histologic, and Molecular Characteristics of Anaplastic Lymphoma Kinase-positive Primary Cutaneous Anaplastic Large Cell Lymphoma. American Journal of Surgical Pathology, 2020, 44, 776-781.	2.1	25
313	Granzyme B-expressing peripheral T-cell lymphomas: neoplastic equivalents of activated cytotoxic T cells with preference for mucosa-associated lymphoid tissue localization. Blood, 1994, 84, 3785-91.	0.6	25
314	Oral etoposide in the treatment of cutaneous large-cell lymphomas. A preliminary report of four cases. British Journal of Dermatology, 1992, 127, 524-528.	1.4	24
315	Mosaicism of the 5q deletion as assessed by interphase FISH is a common phenomenon in MDS and restricted to myeloid cells. Leukemia, 1997, 11, 519-523.	3.3	24
316	Analysis of T ell clonality in bone marrow of patients with acquired aplastic anaemia. British Journal of Haematology, 1997, 96, 85-91.	1.2	24
317	HLA class II restricted T-cell receptor gene transfer generates CD4+ T cells with helper activity as well as cytotoxic capacity. Gene Therapy, 2005, 12, 1686-1695.	2.3	24
318	Prevalence and risk factors of inflammatory acne vulgaris in rural and urban Ghanaian schoolchildren. British Journal of Dermatology, 2009, 161, 475-477.	1.4	24
319	Kidney Transplant Recipients with Cutaneous Squamous Cell Carcinoma Have an Increased Risk of Internal Malignancy. Journal of Investigative Dermatology, 2012, 132, 2176-2183.	0.3	24
320	Mycosis fungoides variants—clinicopathologic features, differential diagnosis, and treatment. Seminars in Cutaneous Medicine and Surgery, 2018, 37, 11-17.	1.6	24
321	Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-aza-2'-deoxycytidine. Leukemia, 1993, 7, 1005-11.	3.3	24
322	Intermediate and high dose Ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC leukemia cooperative group phase II study. European Journal of Cancer & Clinical Oncology, 1988, 24, 1721-1725.	0.9	23
323	Gastrointestinal complications of cytosine-arabinoside chemotherapy: findings on plain abdominal radiographs American Journal of Roentgenology, 1990, 154, 95-98.	1.0	23
324	CD44 Antibody Stimulates Adhesion of Peripheral Blood T Cells to Keratinocytes Through the Leukocyte Function–Associated Antigen-1/Intercellular Adhesion Molecule-1 Pathway. Journal of Investigative Dermatology, 1993, 100, 424-428.	0.3	23

#	Article	IF	CITATIONS
325	Biology and treatment of myelodysplastic syndromes â€" developments in the past decade. Annals of Hematology, 1993, 66, 107-115.	0.8	23
326	High-dose Ara-C for remission induction and consolidation of previously untreated adults with ALL or lymphoblastic lymphoma. Annals of Hematology, 1995, 70, 71-74.	0.8	23
327	Proliferation of precursor Bâ€ineage acute lymphoblastic leukaemia by activating the CD40 antigen. British Journal of Haematology, 1996, 95, 319-326.	1.2	23
328	Classification of cutaneous lymphomas: crosstalk between pathologist and clinician. Current Diagnostic Pathology, 1998, 5, 23-33.	0.4	23
329	Proteolytic Enzyme Levels Are Increased During Granulocyte Colony-Stimulating Factor-Induced Hematopoietic Stem Cell Mobilization in Human Donors but Do Not Predict the Number of Mobilized Stem Cells. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 513-521.	1.8	23
330	Expression of programmed deathâ€1 in skin biopsies of benign inflammatory vs. lymphomatous erythroderma. British Journal of Dermatology, 2014, 171, 499-504.	1.4	23
331	Programmed deathâ€1 expression in cutaneous Bâ€cell lymphoma. Journal of Cutaneous Pathology, 2014, 41, 14-21.	0.7	23
332	Amsacrine with high-dose cytarabine in acute leukemia. Cancer Treatment Reports, 1985, 69, 1447-8.	0.5	23
333	The human interleukin-6 receptor ? chain gene is localized on chromosome 1 band q21. Human Genetics, 1993, 90, 542-4.	1.8	22
334	Costs of Diagnosis, Treatment, and Follow Up of Patients with Acute Myeloid Leukemia in the Netherlands. Journal of Hematotherapy and Stem Cell Research, 2001, 10, 187-192.	1.8	22
335	Varicella zoster virus (VZV)-related progressive outer retinal necrosis (PORN) after allogeneic stem cell transplantation. Bone Marrow Transplantation, 2005, 36, 467-469.	1.3	22
336	Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia. Haematologica, 2010, 95, 914-921.	1.7	22
337	Mechanisms underlying hematopoietic stem cell mobilization induced by the CXC chemokine interleukin-8. Current Opinion in Hematology, 1999, 6, 152.	1.2	22
338	Correction of neutropenia associated with chronic lymphocytic leukaemia following treatment with granulocyte-macrophage colony-stimulating factor. Annals of Hematology, 1991, 62, 32-34.	0.8	21
339	Umbilical cord blood contains normal frequencies of cytotoxic T-lymphocyte precursors (ctlp) and helper T-lymphocyte precursors against noninherited maternal antigens and noninherited paternal antigens. Annals of Hematology, 1996, 72, 260-264.	0.8	21
340	Processing of natural and recombinant CXCR3-targeting chemokines and implications for biological activity. FEBS Journal, 2001, 268, 4992-4999.	0.2	21
341	Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial. Leukemia, 2006, 20, 1723-1730.	3.3	21
342	Reduced ILâ€1Ra/ILâ€1 ratio in ultraviolet Bâ€exposed skin of patients with polymorphic light eruption. Experimental Dermatology, 2009, 18, 212-217.	1.4	21

#	Article	IF	CITATIONS
343	De novo induced mutations in the deoxycytidine kinase (dck) gene in rat leukemic clonal cell lines confer resistance to cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC). Leukemia, 1995, 9, 1032-8.	3.3	21
344	p53 and bcl-2 expression do not correlate with prognosis in primary cutaneous large T-cell lymphomas. Journal of Cutaneous Pathology, 1997, 24, 462-467.	0.7	20
345	Differences in Epstein-Barr Virus Expression Between Primary and Secondary Cutaneous Angiocentric Lymphomas. Archives of Dermatology, 1998, 134, 479.	1.7	20
346	Impaired Expression of CD28 on T Cells in Hairy Cell Leukemia. Clinical Immunology, 1999, 93, 256-262.	1.4	20
347	Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40: a phase II study for efficacy and feasibility by HOVON. Leukemia, 2012, 26, 1726-1729.	3.3	20
348	MicroRNA Profiling of Primary Cutaneous Large B-Cell Lymphomas. PLoS ONE, 2013, 8, e82471.	1.1	20
349	Plaque stage folliculotropic mycosis fungoides: histopathologic features and prognostic factors in a series of 40 patients. Journal of Cutaneous Pathology, 2020, 47, 241-250.	0.7	20
350	Deregulation of JAK2 signaling underlies primary cutaneous CD8 ⁺ aggressive epidermotropic cytotoxic T-cell lymphoma. Haematologica, 2022, 107, 702-714.	1.7	20
351	Quality of life in patients with Mycosis Fungoides and Sézary Syndrome: a systematic review of the literature. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2377-2387.	1.3	20
352	Palmar-Plantar Skin Changes and Cytarabine. Annals of Internal Medicine, 1985, 103, 805.	2.0	19
353	Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia. British Journal of Cancer, 1988, 58, 730-733.	2.9	19
354	Primary Cutaneous B-Cell Lymphomas. Leukemia and Lymphoma, 1994, 14, 213-218.	0.6	19
355	Relation between expression of adhesion molecules and clinical behavior in cutaneous follicle center cell lymphomas. Journal of the American Academy of Dermatology, 1997, 37, 34-40.	0.6	19
356	The role of cytokines and hematopoietic growth factors in the autocrine/paracrine regulation of inducible hematopoiesis. Annals of Hematology, 1997, 75, 27-31.	0.8	19
357	Primary cutaneous lymphomas. Current Opinion in Oncology, 2000, 12, 419-425.	1.1	19
358	Chemical exposures other than arsenic are probably not important risk factors for squamous cell carcinoma, basal cell carcinoma and malignant melanoma of the skin. British Journal of Dermatology, 2005, 152, 194-197.	1.4	19
359	Characterization of graft-versus-leukemia responses in patients treated for advanced chronic lymphocytic leukemia with donor lymphocyte infusions after in vitro T-cell depleted allogeneic stem cell transplantation following reduced-intensity conditioning. Leukemia, 2007, 21, 2569-2574.	3.3	19
360	Primary cutaneous lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2009, 20, iv115-iv118.	0.6	19

#	Article	IF	CITATIONS
361	Results of induction and consolidation treatment with intermediate and highâ€dose cytosine arabinoside and mâ€Amsa of patients with poorâ€risk acute myelogeneous leukaemia. European Journal of Haematology, 1988, 40, 198-204.	1.1	19
362	Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group. Haematologica, 2010, 95, 1489-1495.	1.7	19
363	Predictive impact of allele-matching and EBMT risk score for outcome after T-cell depleted unrelated donor transplantation in poor-risk acute leukemia and myelodysplasia. Leukemia, 2011, 25, 1548-1554.	3.3	19
364	Recommendations for the Optimal Radiation Dose in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma: A Report of the Dutch Cutaneous Lymphoma Group. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1279-1285.	0.4	19
365	Evaluation of treatment results in multifocal primary cutaneous anaplastic large cell lymphoma: report of the Dutch Cutaneous Lymphoma Group. British Journal of Dermatology, 2018, 179, 724-731.	1.4	19
366	Immunohistochemical studies using monoclonal antibodies on lymph nodes from patients with mycosis fungoides and Sézary's syndrome. American Journal of Pathology, 1985, 120, 46-54.	1.9	19
367	Is mycosis fungoides exacerbated by fluoxetine?. Journal of the American Academy of Dermatology, 1996, 35, 635-636.	0.6	18
368	Pentoxifylline inhibits human T-cell adhesion to dermal endothelial cells. Archives of Dermatological Research, 1997, 289, 189-193.	1.1	18
369	Long-term survival in adolescent and adult acute lymphoblastic leukemia. Cancer, 2006, 52, 30-34.	2.0	18
370	Involvement of caspase-8 in chemotherapy-induced apoptosis of patient derived leukemia cell lines independent of the death receptor pathway and downstream from mitochondria. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 181-193.	2.2	18
371	Bone marrow examination has limited value in the staging of patients with an anaplastic large cell lymphoma first presenting in the skin. Retrospective analysis of 107 patients. British Journal of Dermatology, 2008, 159, 1148-51.	1.4	18
372	Diagnostic and prognostic significance of <i>CDKN2A</i> / <i>CDKN2B</i> deletions in patients with transformed mycosis fungoides and primary cutaneous CD30-positive lymphoproliferative disease. British Journal of Dermatology, 2015, 172, 784-788.	1.4	18
373	Should we be imaging lymph nodes at initial diagnosis of earlyâ€stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study*. British Journal of Dermatology, 2021, 184, 524-531.	1.4	18
374	Anti-LFA-1 blocking antibodies prevent mobilization of hematopoietic progenitor cells induced by interleukin-8. Blood, 1998, 91, 4099-105.	0.6	18
375	High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia. Blood, 2000, 96, 1517-24.	0.6	18
376	The hematopoietic activities of interleukin-1. Biotherapy (Dordrecht, Netherlands), 1989, 1, 263-271.	0.7	17
377	Bone marrow transplantation or chemotherapy as post-remission treatment of adult acute myelogenous leukemia. Annals of Hematology, 1991, 62, 59-63.	0.8	17
378	TCRÎ ³ Î'+ cells expressing VÎ ³ 9VÎ' 2, which normally predominate the blood, are found in the spleens of patients with hairy cell leukemia. Leukemia, 1997, 11, 106-109.	3.3	17

#	Article	IF	CITATIONS
379	UVB-induced leucocyte trafficking in the epidermis of photosensitive lupus erythematosus patients: Normal depletion of Langerhans cells. Experimental Dermatology, 2005, 14, 138-142.	1.4	17
380	Similar Potential to Become Activated and Proliferate but Differential Kinetics and Profiles of Cytokine Production of Umbilical Cord Blood T Cells and Adult Blood Naive and Memory T Cells. Human Immunology, 2006, 67, 874-883.	1.2	17
381	Genome-wide linkage scan for atypical nevi in p16-Leiden melanoma families. European Journal of Human Genetics, 2008, 16, 1135-1141.	1.4	17
382	Differential expression of <scp>TOX</scp> by skinâ€infiltrating T cells in Sézary syndrome and erythrodermic dermatitis. Journal of Cutaneous Pathology, 2015, 42, 604-609.	0.7	17
383	The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and Sézary Syndrome. American Journal of Surgical Pathology, 2018, 42, 726-734.	2.1	17
384	Substrate-specific deoxycytidine kinase deficiency in 1-beta-D-arabinofuranosylcytosine-resistant leukemic cells. Cancer Research, 1990, 50, 6515-9.	0.4	17
385	Experience with Intermediate and High Dose Cytosine Arabinoside in Refractory Acute Leukaemia. Oncology Research and Treatment, 1983, 6, 200-204.	0.8	16
386	Deoxycytidine kinase, thymidine kinase and cytidine deaminase and the formation of ARA-CTP in leukemic cells in different phases of the cell cycle. Leukemia Research, 1990, 14, 363-369.	0.4	16
387	Specthophotmetric quantification of cell-cell adherence by an enzyme-linked immuno-cell adhesion assay. Journal of Immunological Methods, 1990, 132, 51-56.	0.6	16
388	Increase in Ara-C sensitivity in Ara-C sensitive and -resistant leukemia by stimulation of the salvage and inhibition of the de novo pathway. Annals of Hematology, 1992, 65, 26-32.	0.8	16
389	Colony growth of human hematopoietic progenitor cells in the absence of serum is supported by a proteinase inhibitor identified as antileukoproteinase Journal of Experimental Medicine, 1996, 184, 1305-1312.	4.2	16
390	Molecular persistence of chronic myeloid leukemia caused by donor T cells specific for lineage-restricted maturation antigens not recognizing immature progenitor-cells. Leukemia, 2006, 20, 1040-1046.	3.3	16
391	Separation, enrichment, and characterization of human hematopoietic progenitor cells from umbilical cord blood. Annals of Hematology, 1993, 67, 231-236.	0.8	15
392	Pentoxifylline Inhibits T-Cell Adherence to Keratinocytes. Journal of Investigative Dermatology, 1995, 104, 1004-1007.	0.3	15
393	Incidence of mycosis fungoides and SÃ \otimes zary syndrome in the Netherlands between 2000 and 2020. British Journal of Dermatology, 2021, 185, 434-435.	1.4	15
394	TREATMENT OF REFRACTORY ACUTE LEUKAEMIA WITH HIGH DOSE CYTOSINE ARABINOSIDE. British Journal of Haematology, 1982, 51, 497-504.	1.2	14
395	Interleukin-9 stimulates the proliferation of enriched human erythroid progenitor cells: additive effect with GM-CSF. Annals of Hematology, 1993, 66, 45-49.	0.8	14
396	Interleukin-10, interleukin-12, and tumor necrosis factor- \hat{l} ± differentially influence the proliferation of human CD8 + and CD4 + T-cell clones. Annals of Hematology, 1996, 72, 245-252.	0.8	14

#	Article	IF	CITATIONS
397	IP-10 mRNA EXPRESSION IN CULTURED KERATINOCYTES IS SUPPRESSED BY INHIBITION OF PROTEIN KINASE-C AND TYROSINE KINASE AND ELEVATION OF CAMP. Cytokine, 1999, 11, 469-475.	1.4	14
398	MICA Gene Polymorphism is Not Associated With an Increased Risk for Skin Cancer. Journal of Investigative Dermatology, 2002, 118, 686-691.	0.3	14
399	Epidermal transit of replication-arrested, undifferentiated keratinocytes in UV-exposed XPC mice: An alternative to in situ apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18980-18985.	3.3	14
400	Differential activation of the death receptor pathway in human target cells induced by cytotoxic T lymphocytes showing different kinetics of killing. Haematologica, 2007, 92, 1671-1678.	1.7	14
401	Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission. Haematologica, 2008, 93, 834-841.	1.7	14
402	Short-term intensive treatment (V.A.A.P.) of adult acute lymphoblastic leukemia and lymphoblastic lymphoma. European Journal of Haematology, 2009, 41, 489-495.	1.1	14
403	Rapamycin impairs UV induction of mutantâ€p53 overexpressing cell clusters without affecting tumor onset. International Journal of Cancer, 2012, 131, 1267-1276.	2.3	14
404	Wholeâ€genome analysis uncovers recurrent <i>IKZF1</i> inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm. Genes Chromosomes and Cancer, 2020, 59, 295-308.	1.5	14
405	HOXC4, HOXC5, and HOXC6 expression in primary cutaneous lymphoid lesions. High expression of HOXC5 in anaplastic large-cell lymphomas. American Journal of Pathology, 1997, 151, 1067-74.	1.9	14
406	Development of pulmonary leukostasis in experimental myelocytic leukemia in the Brown-Norway rat. Leukemia, 1992, 6, 142-9.	3.3	14
407	Experience with intermediate- and high-dose cytosine arabinoside in relapsed and refractory acute leukaemia. Netherlands Journal of Medicine, 1983, 26, 215-9.	0.6	14
408	Accelerated reconstitution of platelets and erythrocytes after syngeneic transplantation of bone marrow cells derived from thrombopoietin pretreated donor mice. Blood, 1995, 86, 3308-13.	0.6	14
409	Preliminary results with 5-aza-2'-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC Leukemia Cooperative Group. Leukemia, 1993, 7 Suppl 1, 49-50.	3.3	14
410	Regulatory effects of T cell lymphokines on cytokine gene expression in monocytes. Lymphokine and Cytokine Research, 1993, 12, 457-64.	0.7	14
411	Presence of Epstein-Barr virus in extranodal T-cell lymphomas: differences in relation to site. Blood, 1994, 83, 1612-8.	0.6	14
412	Neurological complications in patients with cutaneous T-cell lymphoma. British Journal of Dermatology, 1986, 114, 359-366.	1.4	13
413	Pentostatin ($2\hat{a}\in^2$ -deoxycoformycin) for the treatment of lymphoid neoplasms. Cancer Treatment Reviews, 1990, 17, 213-215.	3.4	13
414	Absence of mutations in the RET gene in acute myeloid leukemia. Annals of Hematology, 1997, 75, 87-90.	0.8	13

#	Article	IF	CITATIONS
415	Secondary T-acute lymphoblastic leukaemia mimicking blast crisis in chronic myeloid leukaemia. British Journal of Haematology, 1999, 106, 104-106.	1.2	13
416	Recruitment of leukemic cells from G0 phase of the cell cycle by interferons results in conversion of resistance to daunorubicin. Leukemia, 2003, 17, 2049-2051.	3.3	13
417	Recent advances in primary cutaneous B-cell lymphomas. Current Opinion in Oncology, 2014, 26, 230-236.	1.1	13
418	High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT. Bone Marrow Transplantation, 2015, 50, 341-347.	1.3	13
419	Quantitative electron microscopy in the early diagnosis of cutaneous T-cell lymphomas. A long-term follow-up study of 77 patients. American Journal of Pathology, 1986, 123, 166-73.	1.9	13
420	Abnormally activated T lymphocytes in the spleen of patients with hairy-cell leukemia. Leukemia, 1994, 8, 2095-101.	3.3	13
421	Percentage of S-phase cells in bone marrow aspirates, biopsy specimens and bone marrow aspirates corrected for blood dilution from patients with acute leukemia. Leukemia Research, 1987, 11, 209-213.	0.4	12
422	Differential Diagnosis of Cutaneous Large Cell Lymphomas Using Monoclonal Antibodies Reactive in Paraffin-Embedded Skin Biopsy Specimens. American Journal of Dermatopathology, 1991, 13, 342-349.	0.3	12
423	leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial). Annals of	0.8	rgBT/Overloc
424	No TP63 rearrangements in a selected group of primary cutaneous CD30+ lymphoproliferative disorders with aggressive clinical course. Blood, 2016, 128, 141-143.	0.6	12
425	Folliculotropic mycosis fungoides presenting with a solitary lesion: Clinicopathological features and longâ€term followâ€up data in a series of 9 cases. Journal of Cutaneous Pathology, 2018, 45, 122-128.	0.7	12
426	Acquired N-Linked Glycosylation Motifs in B-Cell Receptors of Primary Cutaneous B-Cell Lymphoma and the Normal B-Cell Repertoire. Journal of Investigative Dermatology, 2019, 139, 2195-2203.	0.3	12
427	Primary cutaneous peripheral Tâ€eell lymphoma, not otherwise specified: results of a multicentre European Organization for Research and Treatment of Cancer (EORTC) cutaneous lymphoma taskforce study on the clinicoâ€pathological and prognostic features. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 658-668.	1.3	12
428	Analysis of helper activity on pokeweed mitogen- and interleukin 2-driven immunoglobulin synthesis by neoplastic T4+ cells Journal of Clinical Investigation, 1985, 76, 2139-2143.	3.9	12
429	Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 667-675.	1.4	12
430	Clinical, histopathological and prognostic features of primary cutaneous acral <scp>CD8</scp> ⁺ Tâ€ell lymphoma and other dermal <scp>CD8</scp> ⁺ cutaneous lymphoproliferations: results of an <scp>EORTC</scp> Cutaneous Lymphoma Group workshop*. British Journal of Dermatology, 2022, 186, 887-897.	1.4	12
431	Continuous infusion of interleukin-6 in sublethally irradiated mice accelerates platelet reconstitution and the recovery of myeloid but not of megakaryocytic progenitor cells in bone marrow. Experimental Hematology, 1993, 21, 1621-7.	0.2	12
432	Persistent clonal excess and skewed T-cell repertoire in T cells from patients with hairy cell leukemia. Blood, 1996, 87, 3795-802.	0.6	12

#	Article	IF	Citations
433	Regulatory activity of neoplastic T cells in Sezary syndrome on in vitro immunoglobulin production. Leukemia Research, 1984, 8, 873-884.	0.4	11
434	Arrayâ€based CGH of primary cutaneous CD8+ aggressive EPIDERMOâ€tropic cytotoxic Tâ€cell lymphoma. Genes Chromosomes and Cancer, 2018, 57, 622-629.	1.5	11
435	VH gene analysis of primary cutaneous B-cell lymphomas: evidence for ongoing somatic hypermutation and isotype switching. Blood, 1998, 92, 3857-64.	0.6	11
436	The significance of Leu 8 negative T cells in lymphoid skin infiltrates: malignant transformation, selective homing or T-cell activation?. British Journal of Dermatology, 1990, 123, 587-593.	1.4	10
437	A simplified assay for measurement of cytosine arabinoside incorporation into DNA in Ara-C-sensitive and-resistant leukemic cells. Cancer Chemotherapy and Pharmacology, 1990, 27, 151-156.	1.1	10
438	Induction of ICAM-1 expression by epidermal keratinocytes via a paracrine pathway possibly involving dermal dendritic cells. Archives of Dermatological Research, 1992, 284, 250-252.	1.1	10
439	Multiple minor histocompatibility antigen disparities between a recipient and four HLA-identical potential sibling donors for bone marrow transplantation. Human Immunology, 1993, 37, 221-228.	1.2	10
440	IL-4 down-regulates IL-2-, IL-3-, and GM-CSF-induced cytokine gene expression in peripheral blood monocytes. Annals of Hematology, 1994, 68, 293-298.	0.8	10
441	CD30-Negative Cutaneous T-Cell Lymphomas Other than Mycosis Fungoides. Surgical Pathology Clinics, 2014, 7, 229-252.	0.7	10
442	Human interleukin for DA cells (HILDA) does not affect the proliferation and differentiation of hematopoietic progenitor cells in human long-term bone marrow cultures. Experimental Hematology, 1992, 20, 6-10.	0.2	10
443	Fournier's gangrene or fulminant necrotizing fasciitis of the scrotum and penis as a complication of granulocytopenia in a patient with acute myelogenous leukaemia (AML). Netherlands Journal of Medicine, 1988, 32, 235-9.	0.6	10
444	Involvement of the complement system in the pathogenesis of pulmonary leukostasis in experimental myelocytic leukemia. Leukemia, 1993, 7, 1608-14.	3.3	10
445	Marrow culture in diffusion chambers in rabbits: III. Effect of endotoxin and leukocyte products on cell production. American Journal of Hematology, 1979, 7, 33-43.	2.0	9
446	Intercellular distribution of HLA-DR and T6 antigens in the epidermis of various dcrmatoses. British Journal of Dermatology, 1985, 113, 802-804.	1.4	9
447	Order of human hematopoietic growth factor and receptor genes on the long arm of chromosome 5, as determined by fluorescence in situ hybridization. Annals of Hematology, 1993, 66, 15-20.	0.8	9
448	The Role of the CD40 Antigen on Malignant B Cells. Leukemia and Lymphoma, 1996, 22, 229-235.	0.6	9
449	Accelerated platelet reconstitution following transplantation of bone marrow cells derived from IL-6-treated donor mice. Annals of Hematology, 1996, 73, 239-245.	0.8	9
450	Factors influencing release of granulocyteâ€macrophage colonyâ€stimulating activity from human mononuclear phagocytes*. European Journal of Haematology, 1988, 41, 352-358.	1.1	9

#	Article	IF	Citations
451	Dietary Immunosuppressants Do Not Enhance UV-Induced Skin Carcinogenesis, and Reveal Discordance between p53-Mutant Early Clones and Carcinomas. Cancer Prevention Research, 2013, 6, 129-138.	0.7	9
452	TOX expression in cutaneous B-cell lymphomas. Archives of Dermatological Research, 2016, 308, 423-427.	1.1	9
453	Outcomes of rare patients with a primary cutaneous CD30+ lymphoproliferative disorder developing extracutaneous disease. Blood, 2020, 135, 769-773.	0.6	9
454	Whole-genome profiling of primary cutaneous anaplastic large cell lymphoma. Haematologica, 2022, 107, 1619-1632.	1.7	9
455	Murine hematopoietic progenitor cells with colony-forming or radioprotective capacity lack expression of the beta 2-integrin LFA-1. Blood, 1999, 93, 107-12.	0.6	9
456	Haemopoietic growth factor tyrosine kinase receptor expression profiles in normal haemopoiesis. British Journal of Haematology, 1996, 94, 236-241.	1.2	8
457	Commentary on "Cutaneous Manifestations of Lymphoma: A Clinical Guide Based on the WHO Classification― Clinical Lymphoma and Myeloma, 2001, 2, 101-102.	2.1	8
458	Cost analysis of CHOP (-like) chemotherapy regimens for patients with newly diagnosed aggressive non-Hodgkin's lymphoma. European Journal of Haematology, 2002, 69, 213-220.	1.1	8
459	Aleukaemic leukaemia cutis in a patient with acute T-cell lymphoblastic leukaemia. Clinical and Experimental Dermatology, 2003, 28, 330-332.	0.6	8
460	Umbilical cord blood–naive T cells but not adult blood–naive T cells require HLA class II on antigen-presenting cells for allo-immune activation. Human Immunology, 2004, 65, 328-339.	1.2	8
461	Pitfalls in diagnosing primary cutaneous aggressive epidermotropic <scp>CD</scp> 8 ⁺ Tâ€cell lymphoma. British Journal of Dermatology, 2019, 180, 411-412.	1.4	8
462	Rationale of a New Classification for the Group of Primary Cutaneous Lymphomas. Seminars in Cutaneous Medicine and Surgery, 2000, 19, 71-77.	1.6	8
463	Clonal hematopoiesis in patients with acquired aplastic anemia. Blood, 1991, 78, 3209-14.	0.6	8
464	Effect of the interval between high dose 1-beta-D-arabinofuranosylcytosine injections on leukemic cell load, intestinal toxicity, and normal hematopoietic stem cells in a rat model for acute myelogenous leukemia. Cancer Research, 1986, 46, 3825-7.	0.4	8
465	Reduction and repopulation of T-lymphocytes after cytoreductive therapy with or without autologous bone marrow rescue. Experimental Hematology, 1986, 14, 173-7.	0.2	8
466	Inhibitory effect of interleukin-4 on the proliferation of acute myeloid leukemia cells with myelo-monocytic differentiation (AML-M4/M5); the role of interleukin-6. Leukemia, 1993, 7, 643-5.	3.3	8
467	Thirty years of progress in cutaneous lymphoma research. Giornale Italiano Di Dermatologia E Venereologia, 2012, 147, 515-21.	0.8	8
468	Primary cutaneous lymphoma: the 2018 update of the WHO-EORTC classification. Presse Medicale, 2022, 51, 104126.	0.8	8

#	Article	IF	Citations
469	B-cell colony growth of malignant and normal B-cells. British Journal of Cancer, 1987, 55, 397-405.	2.9	7
470	APLASTIC ANAEMIA PATIENTS WITH CLONAL Xâ€CHROMOSOME INACTIVATION PATTERN IN HAEMOPOIETIC CELLS EXHIBIT POLYCLONAL TCRγ AND IgH GENE REARRANGEMENTS. British Journal of Haematology, 1996, 93, 326-332.	1.2	7
471	Leukemia Inhibitory Factor Induces In Vivo Expansion of Bone Marrow Progenitor Cells that Accelerate Hematopoietic Reconstitution but Do Not Enhance Radioprotection in Lethally Irradiated Mice. Stem Cells, 1997, 15, 50-55.	1.4	7
472	Unconventional rapid ERK1,2 activation is indispensable for proliferation of the growth factor-independent myeloid leukemic cell line KG1. Leukemia, 1998, 12, 699-704.	3.3	7
473	The Morphology of Dyserythropoiesis in a Patient with Acute Erythroleukaemia Associated with Multiple Myeloma. Scandinavian Journal of Haematology, 1976, 17, 353-368.	0.0	7
474	Point and period prevalences of eczema in rural and urban schoolchildren in Ghana, Gabon and Rwanda. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 488-494.	1.3	7
475	Increased Expression of PLS3 Correlates with Better Outcome in Sézary Syndrome. Journal of Investigative Dermatology, 2017, 137, 754-757.	0.3	7
476	The prognostic significance of chromosomal findings in patients with acute myeloid leukemia in a study comparing the efficacy of autologous and allogeneic bone marrow transplantation. Bone Marrow Transplantation, 1991, 8, 377-81.	1.3	7
477	Jessner's lymphocytic infiltration of the skin. A clinical study of 100 patients. Archives of Dermatology, 1989, 125, 1525-30.	1.7	7
478	Homing and antigenic characterization of a human non-Hodgkin's lymphoma B cell line in severe combined immunodeficient (SCID) mice. Leukemia, 1994, 8, 1385-91.	3.3	7
479	Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice. Experimental Hematology, 1996, 24, 919-26.	0.2	7
480	Correction of abnormal T-cell receptor repertoire during interferon-alpha therapy in patients with hairy cell leukemia. Blood, 1998, 91, 4224-31.	0.6	7
481	Day-6 bone marrow aspirate for the prediction of response to remission induction therapy for acute myelogenous leukaemia. Blut, 1988, 57, 91-95.	1.2	6
482	Cloning of the Dck gene encoding rat deoxycytidine kinase. Gene, 1994, 150, 351-354.	1.0	6
483	A novel RT-PCR-based protein activity truncation assay for direct assessment of deoxycytidine kinase in small numbers of purified leukemic cells. Leukemia, 2000, 14, 1678-1684.	3.3	6
484	Should primary cutaneous Ki-1(CD30)-positive anaplastic large cell lymphoma in childhood be treated with multiple-agent chemotherapy?. Journal of the American Academy of Dermatology, 2001, 45, 638-639.	0.6	6
485	Azathioprine-Induced Microsatellite Instability Is Not Observed in Skin Carcinomas of Organ Transplant Recipients. Journal of Investigative Dermatology, 2009, 129, 1307-1309.	0.3	6
486	XV. Primary cutaneous lymphomas. Annals of Oncology, 2011, 22, iv72-iv75.	0.6	6

#	Article	IF	CITATIONS
487	Tumor-stage mycosis fungoides of the vulva successfully treated with local low-dose radiotherapy. Dermatologic Therapy, 2015, 28, 36-39.	0.8	6
488	The clinical spectrum of mycosis fungoides in Tanzania, East Africa. British Journal of Dermatology, 2017, 176, 1653-1656.	1.4	6
489	Generalized Molluscum Contagiosum Successfully Treated with Interferon-Alpha in a Patient with Folliculotropic Mycosis Fungoides. Case Reports in Dermatology, 2019, 11, 52-56.	0.3	6
490	Ethnicity in mycosis fungoides: white patients present at an older age and with more advanced disease. British Journal of Dermatology, 2019, 180, 1264-1265.	1.4	6
491	Rationale of a new classification for the group of primary cutaneous lymphomas. Seminars in Cutaneous Medicine and Surgery, 2000, 19, 71-7.	1.6	6
492	Thrombocytopenic purpura, coeliac disease and IgA deficiency. Netherlands Journal of Medicine, 1986, 29, 165-6.	0.6	6
493	HOXC4, HOXC5, and HOXC6 expression in non-Hodgkin's lymphoma: preferential expression of the HOXC5 gene in primary cutaneous anaplastic T-cell and oro-gastrointestinal tract mucosa-associated B-cell lymphomas. Blood, 1997, 90, 4116-25.	0.6	6
494	Hairy cell leukemia-specific recognition by multiple autologous HLA-DQ or DP-restricted T-cell clones. Blood, 1999, 93, 251-9.	0.6	6
495	Solitary Plasmocytoma of the Vagina. Acta Haematologica, 1981, 66, 140-144.	0.7	5
496	Hairy cell leukemia: In-vitro proliferation and pseudo-colony formation. Leukemia Research, 1987, 11, 911-921.	0.4	5
497	Selective Response of CD5+B Cell Malignancies to Activation of the CD72 Antigen. Clinical Immunology and Immunopathology, 1998, 87, 42-49.	2.1	5
498	Comparable engraftment and chimerism kinetics using oral and intravenous fludarabine as part of a reduced intensity conditioning regimen. Bone Marrow Transplantation, 2008, 42, 137-138.	1.3	5
499	Quantitation of tumour development correlates with prognosis in tumour stage (stage IIB) mycosis fungoides. British Journal of Dermatology, 2014, 170, 1080-1086.	1.4	5
500	Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas. Archives of Dermatology, 2001, 137, 901-5.	1.7	5
501	Engraftment potential into NOD/SCID mice of CD34+ cells derived from human fetal liver as compared to fetal bone marrow. Haematologica, 2001, 86, 1021-8.	1.7	5
502	Primary lymphoblastic non-Hodgkin's lymphoma of the skin. British Journal of Dermatology, 1981, 104, 333-338.	1.4	4
503	PREDICTION OF RESPONSE OF ACUTE NON-LYMPHOCYTIC LEUKAEMIA TO THERAPY WITH †HIGH DOSE†CYTOSINE ARABINOSIDE. British Journal of Haematology, 1985, 59, 733-734.	1.2	4
504	Human B cell colony assays. Blut, 1987, 55, 189-198.	1.2	4

#	Article	IF	CITATIONS
505	No Acceleration of UV-Induced Skin Carcinogenesis from Evenly Spread Dietary Intake of Cyclosporine in Contrast to Oral Bolus Dosages. Transplantation, 2013, 96, 871-876.	0.5	4
506	Corresponding anaplastic lymphoma kinase–tropomyosin 3 (ALK-TPM3) fusion in a patient with a primary cutaneous anaplastic large-cell lymphoma and a Spitz nevus. JAAD Case Reports, 2019, 5, 970-972.	0.4	4
507	Interleukin 4 down-regulates the expression of CD14 and the production of interleukin 6 in acute myeloid leukemia cells. Lymphokine and Cytokine Research, 1991, 10, 457-61.	0.7	4
508	Colony growth of normal and neoplastic cells in various concentrations of methylcellulose. Experimental Hematology, 1988, 16, 922-8.	0.2	4
509	The in vivo diffusion chamber technique for bone marrow or blood cell culture. Blut, 1981, 42, 59-67.	1.2	3
510	E-rosette positive acute lymphoblastic leukaemia in adolescents and adults. British Journal of Haematology, 1983, 55, 295-304.	1.2	3
511	A comparison of two culture techniques: An in vitro & an in vivo tumour colony-forming assay. British Journal of Cancer, 1985, 52, 713-717.	2.9	3
512	Detection of partial cDNA sequences differentially expressed in patients with myelodysplasia. Annals of Hematology, 1996, 72, 231-236.	0.8	3
513	Extramedullary hematopoietic growth factor and cytokine gene expression indicate endocrine regulation of hematopoiesis in patients with acute appendicitis. Annals of Hematology, 1997, 75, 201-205.	0.8	3
514	The risk of cancer is not increased in patients with multiple kidney transplantations. Transplant Immunology, 2012, 27, 189-194.	0.6	3
515	A rare case of cutaneous Epstein-Barr virus–negative intravascular cytotoxic T-cell lymphoma. JAAD Case Reports, 2019, 5, 548-551.	0.4	3
516	High Dose Intensive Chemotherapy, as Is Standard in Childhood Leukemia, Is Feasible and Efficacious in Adult Patients with Acute Lymphoblastic Leukemia (ALL) up to the Age of 40: Results From the Dutch-Belgian HOVON-70 Study Blood, 2009, 114, 323-323.	0.6	3
517	Primary Cutaneous Follicle Center Lymphomas (PCFCL) Express Heavily Mutated B-Cell Receptors with Acquired N-Glycosylation Motifs and Lack Ongoing Somatic Hypermutation. Blood, 2018, 132, 1573-1573.	0.6	3
518	Experimental myelocytic leukemia in the Brown-Norway rat as a model for pulmonary leukostasis. American Journal of Pathology, 1991, 138, 777-80.	1.9	3
519	Total skin electron beam therapy for cutaneous T-cell lymphomas in the Netherlands: A retrospective analysis of treatment outcomes and selection for high or low dose schedule. Clinical and Translational Radiation Oncology, 2022, 33, 77-82.	0.9	3
520	Frequency and prognostic significance of clonal T-cell receptor beta-gene rearrangements in the peripheral blood of patients with mycosis fungoides. Archives of Dermatology, 1992, 128, 1602-7.	1.7	3
521	Serum monocyte colony-stimulating factor, erythropoietin and interleukin-6 in relation to pancytopenia in hairy cell leukemia. Leukemia, 1992, 6, 735-7.	3 . 3	3
522	Lymphomatoid papulosis. Dermatologic Clinics, 1985, 3, 735-47.	1.0	3

#	Article	IF	CITATIONS
523	Results of a multicentre study of the treatment of acute lymphoblastic leukaemia in adolescents and adults (1978-1981). Netherlands Journal of Medicine, 1982, 25, 303-7.	0.6	3
524	Constitutive in vivo cytokine and hematopoietic growth factor gene expression in the bone marrow and peripheral blood of healthy individuals. Blood, 1995, 85, 2038-44.	0.6	3
525	Direct display of hematopoietic tyrosine kinase receptor expression profiles in KG1 cells by PCR using degenerate primers. Leukemia, 1996, 10, 1395-9.	3.3	3
526	Unrelated bone marrow transplantation as a rescue procedure following inadvertent loss of an autologous bone marrow graft. Bone Marrow Transplantation, 1996, 18, 461-3.	1.3	3
527	Characterization of a novel malignant B cell line with $t(14;18)$ and $t(4;11)$ established from a patient with acute monoblastic leukemia. Experimental Hematology, 1997, 25, 1062-8.	0.2	3
528	Preliminary results of consolidation therapy with high-dose cytosine arabinoside for patients with bad-risk or relapsed acute leukemia or lymphoblastic non-Hodgkin's lymphoma. European Journal of Cancer & Clinical Oncology, 1987, 23, 401-405.	0.9	2
529	Recent developments in the early diagnosis of mycosis fungoides and Sézary's syndrome. European Journal of Cancer & Clinical Oncology, 1987, 23, 1581-1583.	0.9	2
530	Deoxycoformycin in Therapy of Refractory Lymphoid Neoplasms. Oncology Research and Treatment, 1988, 11, 35-37.	0.8	2
531	Sublocalization of the breakpoints of a $t(5;16)$ in myelodysplasia. Cancer Genetics and Cytogenetics, 1998, 100, 5-9.	1.0	2
532	Tumor necrosis factor alpha (Tnf- \hat{l}_{\pm}) Production by acute myeloid leukemic (Aml) Blasts results in impaired proliferation of normal hematopoietic progenitor cells (Hpc). Experimental Hematology, 2000, 28, 69-70.	0.2	2
533	Clear cell acanthoma on the dorsum of the hand. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 378-380.	1.3	2
534	p16 immunostaining in keratinocytic neoplasia in organ transplant recipients: Bowen's disease shows a characteristic pattern. Journal of Cutaneous Pathology, 2017, 44, 28-33.	0.7	2
535	Serum and cutaneous transcriptional expression levels of IL31 are minimal in cutaneous T cell lymphoma variants. Biochemistry and Biophysics Reports, 2021, 26, 101007.	0.7	2
536	High-dose Ara-C for remission induction and consolidation of previously untreated adults with ALL or lymphoblastic lymphoma. Annals of Hematology, 1995, 70, 71-74.	0.8	2
537	Up-Front Window Trial of Gemtuzumab Ozogamicin (GO) in Previously Untreated Elderly Patients with AML: An EORTC Leukemia Group Study Blood, 2004, 104, 877-877.	0.6	2
538	Allogeneic Stem Cell Transplantation (Allo-SCT) in the Management of Advanced Waldenstrom's Macroglobulinemia (WM) Blood, 2007, 110, 619-619.	0.6	2
539	Gall bladder perforation in response to chemotherapy in a patient with a histiocytic lymphoma. Netherlands Journal of Medicine, 1988, 33, 78-82.	0.6	2
540	Extranodal non-Hodgkin's lymphoma. Netherlands Journal of Medicine, 1988, 33, 49-51.	0.6	2

#	Article	IF	CITATIONS
541	Monoclonal antibodies in the histopathological diagnosis of non-Hodgkin lymphomas. Netherlands Journal of Medicine, 1985, 28, 138-41.	0.6	2
542	Classification of primary cutaneous large cell lymphomas. Dermatologic Clinics, 1994, 12, 361-73.	1.0	2
543	Mycosis fungoides with extracutaneous localization in the breast. British Journal of Dermatology, 1996, 134, 1125-30.	1.4	2
544	An in vivo clonogenic assay for human tumors using plasma clot diffusion chambers implanted in mice. European Journal of Cancer & Clinical Oncology, 1985, 21, 127-134.	0.9	1
545	Radioresistant pseudo-colony formation in the PHA-leukocyte feeder colony assay. Leukemia Research, 1988, 12, 917-922.	0.4	1
546	(C11) Clonality of hematopoiesis in patients with aplastic anemia and myelodysplastic syndromes. Leukemia Research, 1991, 15, 7.	0.4	1
547	GM-CSF and IL-3 in Myelodysplastic Syndromes at Low Risk of Developing Acute Leukemia (MDS-LR). Leukemia and Lymphoma, 1992, 7, 64-64.	0.6	1
548	71 Clonality of hematopoiesis in myelodysplasia. Leukemia Research, 1997, 21, S19.	0.4	1
549	Classification and recommended treatment options for folliculotropic mycosis fungoides. Expert Opinion on Orphan Drugs, 2018, 6, 35-45.	0.5	1
550	Allogeneic (Allo-) or Autologous (Auto-) Peripheral Blood Stem Cell Transplantation (SCT) Randomized Versus a Second Intensive Consolidation after a Common Induction and Consolidation Course in Patients with Bad Prognosis Myelodysplastic Syndromes and Acute Myelogenous Leukemia Following MDS of More Than 6 Months Duration: The Final Analysis of a Joint Study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukemia Groups Blood, 2005, 106, 794-794.	0.6	1
551	Incidence and Clinical Impact of TET2 Mutations in Acute Myeloid Leukemia Patients Treated within the EORTC/GIMEMA AML-12/06991 AML Trial Blood, 2009, 114, 2609-2609.	0.6	1
552	Antigen-Independent, Autonomous B-Cell Receptor Signaling As a Dominant Candidate Oncogenic Mechanism in ABC DLBCL. Blood, 2016, 128, 778-778.	0.6	1
553	Treatment of acute myelogenous leukaemia in adults. A retrospective study of 70 patients (1968-1973). Netherlands Journal of Medicine, 1975, 18, 17-28.	0.6	1
554	Systemic polychemotherapy in patients with mycosis fungoides and lymph node involvement: a follow-up study of 17 patients. Acta Dermato-Venereologica, 1985, 65, 179-83.	0.6	1
555	Haematopoietic growth factors. Netherlands Journal of Medicine, 1989, 35, 151-68.	0.6	1
556	New techniques in the evaluation of cutaneous T-cell lymphoma. Dermatologic Clinics, 1985, 3, 665-72.	1.0	1
557	Bone marrow disorders in Hodgkin's disease: cyclic pancytopenia coinciding with Pel-Ebstein fever. Netherlands Journal of Medicine, 1983, 26, 74-6.	0.6	1
558	The diagnostic value of morphometry on blood lymphocytes in erythrodermic actinic reticuloid. Archives of Dermatology, 1995, 131, 1298-303.	1.7	1

#	Article	IF	CITATIONS
559	Mass Cytometric Analysis of Early-Stage Mycosis Fungoides. Cells, 2022, 11, 1062.	1.8	1
560	Marrow culture in diffusion chambers in rabbits. II. Effect of competing demands for red cell and white cell production on cell growth. Blood, 1978, 51, 1129-1135.	0.6	1
561	Willem A. van Vloten zum 60. Geburtstag. Hautarzt, 2001, 52, 547-548.	1.2	0
562	Cutaneous lymphomas. Lancet Oncology, The, 2005, 6, 839.	5.1	0
563	Limited effect of chemotherapy in cutaneous lymphoma. Blood, 2015, 125, 4-5.	0.6	0
564	176 The Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) Study identifies clinical prognostic markers and establishes the foundation for large-scale translational research in cutaneous lymphoma. Journal of Investigative Dermatology, 2019, 139, S31.	0.3	0
565	Primary Allogeneic T-Cell Responses Against In Vitro Modified Mantle Cell Lymphoma (MCL) Cells: Implications for Adoptive Immunotherapy after HLA-Matched Stem Cell Transplantation (SCT) Blood, 2004, 104, 2118-2118.	0.6	0
566	Retroviral Interference with Execution Pathways in Target Cells To Unravel Mechanisms of Cytotoxic T Cell-Mediated Cell Death Blood, 2004, 104, 1267-1267.	0.6	0
567	First Line Treatment of Aggressive Cutaneous NK/T Cell Lymphomas Based on High Dose Cytarabine and Stem Cell Transplantation Does Not Lead to Durable Remissions Blood, 2006, 108, 4669-4669.	0.6	0
568	The B-Cell Receptor of Primary Cutaneous Follicle Center Lymphoma: Implications for Pathogenesis. Blood, 2016, 128, 4136-4136.	0.6	0
569	Post remission treatment in acute myelogenous leukaemia in first remission. The EORTC experience. EORTC Leukemia Cooperative Group. Bone Marrow Transplantation, 1989, 4 Suppl 3, 72.	1.3	0
570	Comparison of intensive consolidation therapy and autologous bone marrow transplantation in acute myeloid leukaemia. The Leiden experience. Bone Marrow Transplantation, 1989, 4 Suppl 3, 73.	1.3	0
571	The unrelated bone marrow donor. Bone Marrow Transplantation, 1988, 3, 371-7.	1.3	0
572	Effect of calcitriol on growth, differentiation, chemokine mRNA expression of cultured keratinocytes and on keratinocyte-T cell binding. Acta Dermato-venereologica Supplementum, 1994, 186, 52-4.	0.0	0
573	Tumor Clone Frequency Calculation Using High-Throughput Sequencing of the $TCR^{\hat{1}2}$ Gene in Patients with Folliculotropic Mycosis Fungoides. Journal of Investigative Dermatology, 2022, 142, 2544-2546.e2.	0.3	0